Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Semaglutide, originally developed as a medication for managing type 2 diabetes, has gained attention for its remarkable efficacy in promoting weight loss
In a November 4, 2024, press release, the company highlighted preliminary DIO model data: "[P]eripherally-restricted nimacimab achieve[d] significant dose-dependent weight loss" and "[p]reliminary data shows that nimacimab achieves desired metabolic outcomes." Three days later, CEO Dhillon reinforced this on an earnings call: "We believe nimacimabs first-in-class profile as a perfectly targeting CB1 inhibitor offers the right combination of efficacy and safety." The Q3 2024 10-Q echoed the theme, touting nimacimab's potential to "positively impact metabolic disorders including obesity." This optimism escalated
GLP-1 is a naturally occurring hormone that signals fullness to the brain and assists in managing food intake and blood sugar levels
Avoid making changes to your regimen on your own
Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats
Understanding GLP-1 Agonists: Firstly, its essential to understand what GLP-1 agonists are
